

10/509,300
10/11/2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/Capplus enhanced with utility model patents from China
NEWS 6 JUL 16 Capplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/Capplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 BEILSTEIN updated with new compounds
NEWS 12 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 13 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents
NEWS 14 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS 15 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16 AUG 27 USPATOLD now available on STN
NEWS 17 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19 SEP 13 FORIS renamed to SOFIS
NEWS 20 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 21 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS 22 SEP 17 Capplus coverage extended to include traditional medicine patents
NEWS 23 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 24 OCT 02 CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:12:17 ON 11 OCT 2007

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:12:35 ON 11 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

DICTIONARY FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> E "LYSOPHOSPHATIDYLCHOLINE"/CN 25

E1 1 LYSOPHOSPHATIDIC ACID:ACYL-COA ACYLTRANSFERASE/CN

E2 1 LYSOPHOSPHATIDIC ACIDS, ESTERS WITH CHOLINE/CN

E3 1 --> LYSOPHOSPHATIDYLCHOLINE/CN

E4 1 LYSOPHOSPHATIDYLCHOLINE ACYLHYDROLASE/CN

E5 1 LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE/CN

E6 1 LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE (HUMAN GENE LPCAT

ISOENZYME 1)/CN

E7 1 LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE (MOUSE LUNG GENE LPCAT

ISOENZYME 1)/CN

E8 1 LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE (RAT GENE LPCAT

ISOENZYME 1 C-TERMINAL FRAGMENT)/CN

E9 1 LYSOPHOSPHATIDYLCHOLINE ARACHIDONOYLTRANSFERASE/CN

E10 1 LYSOPHOSPHATIDYLCHOLINE HYDROLASE/CN

E11 1 LYSOPHOSPHATIDYLCHOLINE LYSOPHOSPHOLIPASE/CN

E12 1 LYSOPHOSPHATIDYLCHOLINE PHOSPHOLIPASE/CN

E13 1 LYSOPHOSPHATIDYLCHOLINE PHOSPHOLIPASE C/CN

E14 1 LYSOPHOSPHATIDYLCHOLINE TRANSACYLASE/CN

E15 1 LYSOPHOSPHATIDYLCHOLINE-LYSOPHOSPHATIDYLCHOLINE

ACYLTRANSFERASE/CN

E16 1 LYSOPHOSPHATIDYLCHOLINES/CN

E17 1 LYSOPHOSPHATIDYLCHOLINES, 1-ACYL/CN

E18 1 LYSOPHOSPHATIDYLCHOLINES, BOVINE HEART/CN

E19 1 LYSOPHOSPHATIDYLCHOLINES, C14-18-ALKYL ANALOGS/CN

E20 1 LYSOPHOSPHATIDYLCHOLINES, EGG/CN

E21 1 LYSOPHOSPHATIDYLCHOLINES, EGG YOLK,

12-((7-NITRO-2,1,3-BENZOXADIAZOL-4-YL)AMINO)DODECANOATES (ESTERS)/CN

E22 1 LYSOPHOSPHATIDYLCHOLINES, EGG YOLK,

6-((7-NITRO-2,1,3-BENZOXADIAZOL-4-YL)AMINO)HEXANOATES (ESTERS)/CN

E23 1 LYSOPHOSPHATIDYLCHOLINES, L-A-/CN

E24 1 LYSOPHOSPHATIDYLCHOLINES, LIVER/CN
E25 1 LYSOPHOSPHATIDYLCHOLINES, RAPE-OIL/CN

=> S E3

L1 1 LYSOPHOSPHATIDYLCHOLINE/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.55 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 9008-30-4 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may
result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN Lysophosphatidylcholines (CA INDEX NAME)

OTHER NAMES:

CN 2-Lysophosphatidylcholines

CN Blendmax 322D

CN Blendmax K

CN Cosmesome L 10

CN Egg Yolk Lysolecithin LPC 1

CN Glycerophosphocholines

CN Glycerophosphorylcholines

CN L- α -lysophosphatidylcholine

CN Lecimulthin 150

CN LPC 70H

CN Lysocythins

CN Lysoforte

CN Lysolecithins

CN Lysolecithins, L- α -

CN Lysophosphatidic acids, esters with choline

CN Lysophosphatidylcholine

CN Lysophosphatidylcholines, 1-acyl

CN Lysophosphatidylcholines, L- α -

CN Lysoprin

CN Lysozithins

CN Lysozithins, L- α -

CN Phosphatidylcholines, lyso-

CN Phospholipids, lysophosphatidylcholines

CN QPFC-LC 100

CN SLP White Lyso

CN SLP-LPC 70

CN SLP-Pastelyso

CN Sunsoft A 1

MF Unspecified

CI MAN, CTS

LC STN Files: AGRICOLA, ANABSTR, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS,
CHEMLIST, CIN, CSCHEM, IPA, MSDS-OHS, RTECS*, TOXCENTER, USPAT2,
USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: NORL (No role in record)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

7.80

8.01

FILE 'MEDLINE' ENTERED AT 15:13:58 ON 11 OCT 2007

FILE 'CAPLUS' ENTERED AT 15:13:58 ON 11 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:13:58 ON 11 OCT 2007

COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 15:13:58 ON 11 OCT 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1

L2 5 L1

=> d l2 1-5 ibib, abs

L2 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1972:429495 CAPLUS

DOCUMENT NUMBER: 77:29495

TITLE: Influence on plasmaphosphatides by hormonal
contraception

AUTHOR(S): Jipp, P.

CORPORATE SOURCE: I. Med. Universitaetsklin., Kiel, Fed. Rep. Ger.

SOURCE: Thrombosis et Diathesis Haemorrhagica, Supplementum
(1971), No. 49, 141-6

CODEN: TDHSAF; ISSN: 0375-9997

DOCUMENT TYPE: Journal

LANGUAGE: German

AB Treatment of women with Eugynon [6533-00-2] for 3 cycles significantly
increased plasma colamine [141-43-5]-cephalin concentration compared with
untreated controls, but did not affect plasma total phosphatides, lecithin
[8002-43-5], sphingomyelin, or lysolecithin [9008-30-4] values.

L2 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1963:408473 CAPLUS

DOCUMENT NUMBER: 59:8473

ORIGINAL REFERENCE NO.: 59:1468b-d

TITLE: Products of glycerylphosphatide hydrolysis

AUTHOR(S): Ravazzoni, Carla; Donelli, Giorgio; Valerio, Romilde

CORPORATE SOURCE: Carlo Erba Inst. Ther. Res., Milan

SOURCE: Chimica e l'Industria (Milan, Italy) (1962), 44,
1380-2

CODEN: CINMAB; ISSN: 0009-4315

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB L- α -Glycerylphosphorylcholine (I), lysolecithin (II), and
L- α -caprylpalmityllecithin were prepared and purified by paper
chromatography and thin-layer chromatography on silica gel according to
previously described procedures (Tattreie and McArthur, CA 53, 6327i;
Urakami, et al., CA 54, 24419a; Rhodes and Lea, CA 51, 7452e). The Rf
values for the 2 chromatographic procedures for various solvents were
determined and compared with previously reported values by Huennekens, et al.
(CA 48, 4024f). The Rf values determined for I differed most markedly from
those in the literature, being generally much lower. The following data
were obtained (solvent system, compound, its Rf value as obtained by the
authors, and previously reported Rf value given): 8:1 EtOH-H₂O, I, 0.20,
0.70, II, 0.65, 0.89; 8:1 PrOH-H₂O, I, 0.04, 0.25, II, 0.67, 0.61; 8:1:1
PrOH-AcOH-H₂O, I, 0.10, 0.76, II, 0.67, 0.85.

L2 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1963:408472 CAPLUS

DOCUMENT NUMBER: 59:8472
 ORIGINAL REFERENCE NO.: 59:1468b
 TITLE: Association of titanium(IV) alkoxides in benzene
 AUTHOR(S): Martin, R. L.; Winter, G.
 CORPORATE SOURCE: Univ. Melbourne
 SOURCE: Nature (London, United Kingdom) (1963), 197, 687
 CODEN: NATUAS; ISSN: 0028-0836
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB cf. Caughlan, et al., CA 46, 2380g. By x-ray structure detns. of Ti(IV) ethoxide, it cannot be resolved whether average degrees of assocns. greater than three occur. Cryoscopic studies in solvents other than C6H6 are being made.

L2 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1963:408471 CAPLUS
 DOCUMENT NUMBER: 59:8471
 ORIGINAL REFERENCE NO.: 59:1467h,1468a-b
 TITLE: Phosphonic acids. VII. The reaction of sodium diethyl phosphonate with organic disulfides
 AUTHOR(S): Harvey, Ronald G.; Jacobson, Herbert I.; Jensen, Elwood V.
 CORPORATE SOURCE: Univ. of Chicago
 SOURCE: Journal of the American Chemical Society (1963), 85, 1623-6
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 59:8471
 AB NaP(O)(OEt)2 in tetrahydrofuran reacts rapidly with organic disulfides to produce a phosphorothioate ester and a sodium mercaptide. From ethyl disulfide and β -acetamidoethyl disulfide, the resp. products are O,O,S-triethyl phosphorothioate and O,O-diethyl S- β -acetamidoethyl phosphorothioate. Reaction with PhSSEt takes place in one direction only to form O,O,S-triethyl phosphorothioate and sodium thiophenoxide. Unless separated immediately, the phosphorothioate and sodium mercaptide produced interact further to form a sodium dialkyl phosphorothioate and a thio ether. EtSNa is an effective reagent for the monodealkylation of phosphate, phosphonate, and phosphorothioate esters; with the latter substances, a carbon-oxygen bond is cleaved in preference to a simple carbonsulfur bond.

L2 ANSWER 5 OF 5 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.23	48.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

FILE 'REGISTRY' ENTERED AT 15:22:34 ON 11 OCT 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1
 DICTIONARY FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10509300.str



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

chain bonds :

1-2 1-3 1-4 3-5 5-6 6-7 6-8 6-9 9-10 10-11 11-12 11-13 11-14 14-15
15-16 16-17 17-18 17-19 17-20

exact/norm bonds :

1-3 1-4 6-7 10-11 11-12 11-13 11-14

exact bonds :

1-2 3-5 5-6 6-8 6-9 9-10 14-15 15-16 16-17 17-18 17-19 17-20

Match level :


1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS

L3 STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l3 full

FULL SEARCH INITIATED 15:22:52 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 6450 TO ITERATE

100.0% PROCESSED 6450 ITERATIONS

175 ANSWERS

SEARCH TIME: 00.00.01

L4 175 SEA SSS FUL L3


=> d scan

L4 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3,5,9-Trioxa-4-phosphaeicos-19-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, 4-oxide (9CI)

MF C19 H39 N O7 P

CI COM



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file medline caplus wpids uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

220.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.12

FILE 'MEDLINE' ENTERED AT 15:23:14 ON 11 OCT 2007

FILE 'CAPLUS' ENTERED AT 15:23:14 ON 11 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:23:14 ON 11 OCT 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 15:23:14 ON 11 OCT 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l4
SAMPLE SEARCH INITIATED 15:23:22 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 80 TO 360
PROJECTED ANSWERS: 1 TO 40

L5 1595 L4

=> s l5 and (sepsis or septic shock)
L6 14 L5 AND (SEPSIS OR SEPTIC SHOCK)

=> d l6 1-14 ibib, abs, histr
'HISTR' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ibib, abs hitstr

L6 ANSWER 1 OF 14 MEDLINE on STN
ACCESSION NUMBER: 2005140296 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15687351
TITLE: Suppression of HMGB1 release by stearyl
lysophosphatidylcholine:an additional mechanism for its
therapeutic effects in experimental sepsis.
AUTHOR: Chen Guoqian; Li Jianhua; Qiang Xiaoling; Czura Christopher
J; Ochani Mahendar; Ochani Kanta; Ulloa Luis; Yang Huan;
Tracey Kevin J; Wang Ping; Sama Andrew E; Wang Haichao
CORPORATE SOURCE: Department of Emergency Medicine, North Shore University
Hospital, New York University School of Medicine,
Manhasset, NY 11030, USA.
CONTRACT NUMBER: R01 GM-063075 (NIGMS)
SOURCE: Journal of lipid research, (2005 Apr) Vol. 46, No. 4, pp.
623-7. Electronic Publication: 2005-02-01.
Journal code: 0376606. ISSN: 0022-2275.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200507
ENTRY DATE: Entered STN: 18 Mar 2005
Last Updated on STN: 16 Jul 2005
Entered Medline: 15 Jul 2005
AB Stearyl lysophosphatidylcholine (LPC) has recently been proven protective
against lethal sepsis by stimulating neutrophils to eliminate

invading pathogens through an H2O2-dependent mechanism. Here, we demonstrate that stearyl LPC, but not caproyl LPC, significantly attenuates circulating high-mobility group box 1 (HMGB1) levels in endotoxemia and sepsis by suppressing endotoxin-induced HMGB1 release from macrophages/monocytes. Neutralizing antibodies against G2A, a potential cell surface receptor for LPC, partially abrogated stearyl LPC-mediated suppression of HMGB1 release. Thus, stearyl LPC confers protection against lethal experimental sepsis partly by facilitating the elimination of the invading pathogens and partly by inhibiting endotoxin-induced release of a late proinflammatory cytokine, HMGB1.

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2007:895915 CAPLUS
 TITLE: HMGB1 as a potential therapeutic target
 AUTHOR(S): Wang, Haichao; Li, Wei; Goldstein, Richard; Tracey, Kevin J.; Sama, Andrew E.
 CORPORATE SOURCE: Department of Emergency Medicine, North Shore University Hospital, New York University School of Medicine, Manhasset, NY, 11030, USA
 SOURCE: Novartis Foundation Symposium (2007), 280(Sepsis: New Insights, New Therapies), 73-91
 CODEN: NFSYF7; ISSN: 1528-2511
 PUBLISHER: John Wiley & Sons Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. Despite recent advances in antibiotic therapy and intensive care, sepsis remains the most common cause of death in the intensive care units, claiming approx. 225000 victims annually in the USA alone. The pathogenesis of sepsis is attributable, at least in part, to dysregulated systemic inflammatory responses characterized by excessive accumulation of various proinflammatory cytokines. A ubiquitous nuclear protein, high mobility group box 1 (HMGB1), is released by activated macrophages/monocytes, and functions as a late mediator of lethal endotoxemia and sepsis. First, circulating HMGB1 levels are elevated in a delayed fashion (after 16-32h) in endotoxemic and septic animals. Second, administration of recombinant HMGB1 to mice recapitulates many clin. signs of sepsis, including fever, derangement of intestinal barrier function, lung injury and lethal multiple organ failure. Third, administration of anti-HMGB1 antibodies or inhibitors (e.g. Et pyruvate, nicotine, stearyl lysophosphatidylcholine and Chinese herbs such as Angelica sinensis) protects mice against lethal endotoxemia, and rescues mice from lethal exptl. sepsis even when the first doses are given 24 h after onset of sepsis. Taken together, these exptl. data establish HMGB1 as a late mediator of lethal endotoxemia and sepsis with a wider therapeutic window for the clin. management of lethal systemic inflammatory diseases.

IT 17364-19-1, Stearyl lysophosphatidylcholine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (stearyl lysophosphatidylcholine protected exptl. mouse against lethal endotoxemia and sepsis indicating its possible therapeutic potential to treat sepsis in human)

RN 17364-19-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:379975 CAPLUS
DOCUMENT NUMBER: 146:400037
TITLE: Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
INVENTOR(S): Shi, Song; Gentle, Thomas; Moore, Richard
PATENT ASSIGNEE(S): Becton, Dickinson and Company, USA
SOURCE: PCT Int. Appl., 141pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007038758	A2	20070405	WO 2006-US38177	20060927
WO 2007038758	A3	20070913		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 2007111316	A1	20070517	US 2006-541412	20060928
PRIORITY APPLN. INFO.:			US 2005-721833P	P 20050928
			US 2006-762911P	P 20060127
			US 2006-841407P	P 20060830

OTHER SOURCE(S): MARPAT 146:400037

AB The present invention provides methods and compns. useful for the diagnosis or prognosis of a systemic inflammatory condition such as sepsis. The methods involve measuring, over time, the amount of lysophosphatidylcholine in fluid or tissue samples.


IT 17364-16-8, 1-O-Palmitoyl-2-lyso-sn-glyero-3-phosphocholine
19420-57-6, 1-O-Stearoyl-2-lyso-sn-glyero-3-phosphocholine
932699-37-1

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(detection of lysophosphatidylcholine for prognosis or diagnosis of systemic inflammatory conditions)

RN 17364-16-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 19420-57-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-

10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 932699-37-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosane-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, sodium salt (1:1), (7R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

L6 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:151052 CAPLUS

DOCUMENT NUMBER: 146:244343

TITLE: Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

INVENTOR(S): Fogelman, Alan M.; Navab, Mohamad

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: U.S. Pat. Appl. Publ., 313pp., Cont.-in-part of U.S. Ser. No. 423,830.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007032430	A1	20070208	US 2006-407390	20060418
US 6664230	B1	20031216	US 2000-645454	20000824
US 2003045460	A1	20030306	US 2001-896841	20010629
US 6933279	B2	20050823		
CN 1375299	A	20021023	CN 2001-103876	20010823
CN 1739787	A	20060301	CN 2005-10103876	20010823
CN 1911439	A	20070214	CN 2006-10100670	20010823
CN 1931358	A	20070321	CN 2006-10100667	20010823
CN 1931359	A	20070321	CN 2006-10100669	20010823
CN 1943781	A	20070411	CN 2006-10100668	20010823
US 2003171277	A1	20030911	US 2002-187215	20020628
US 7144862	B2	20061205		
US 2003229015	A1	20031211	US 2002-273386	20021016
US 7166578	B2	20070123		
US 2004266671	A1	20041230	US 2003-423830	20030425
US 7199102	B2	20070403		
JP 2006056899	A	20060302	JP 2005-304531	20051019

JP 2006312650
PRIORITY APPLN. INFO.:

A 20061116

JP 2006-220831	20060814
US 2000-645454	A2 20000824
US 2001-896841	A2 20010629
US 2002-187215	A2 20020628
US 2002-273386	A2 20021016
US 2003-423830	A2 20030425
US 2005-676431P	P 20050429
US 2005-697495P	P 20050707
CN 2001-103876	A3 20010823
CN 2001-817280	A3 20010823
CN 2005-10103876	A3 20010823
JP 2002-520844	A3 20010823
WO 2001-US26497	A2 20010823
JP 2005-304531	A3 20051019

OTHER SOURCE(S): MARPAT 146:244343

AB The invention provides novel active agents (e.g. peptides, small organic mols., amino acid pairs, etc.) that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiments, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route. Peptide preparation is included.


IT 17364-16-8D, 1-Palmitoyl-sn-glycero-3-phosphorylcholine, epoxyisoprostane derivs. 19420-57-6D, 1-Stearoyl-sn-glycero-3-phosphorylcholine, epoxyisoprostane derivs.

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(peptidic compds. to treat diseases characterized by inflammatory response)

RN 17364-16-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 19420-57-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:971877 CAPLUS

DOCUMENT NUMBER: 147:323201

TITLE: Synthesis of lysophosphatidylcholine analogs using D-mannitol as a chiral template and their biological activity for sepsis

AUTHOR(S): Heo, Hye Jin; Jung, Jun-Sub; Lee, Jung Ho; Han, Su Young; Bang, Hyun Bae; Song, Dong-Keun; Jun, Jong-Gab

CORPORATE SOURCE: Department of Chemistry, Institute of Natural
Medicine, Infectious Disease Medical Research Center,
Hallym University, Chunchon, 200-702, S. Korea

SOURCE: Bulletin of the Korean Chemical Society (2006), 27(8),
1149-1153
CODEN: BKCSDE; ISSN: 0253-2964

PUBLISHER: Korean Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB LPC analogs including natural and unnatural LPC, 3-L-2-PC, acetylated LPC
and an ethylene glycol derivative are prepared from D-mannitol and their
protective activities against cecal ligation and puncture (CLP)-induced
severe sepsis are compared. The chirality at C-2 in LPC is
required to be (R) for sepsis inhibition, as shown by comparing
the protection activity between LPC and unnatural LPC. The hydroxyl
functionality is also very important and required at C-2 or C-3 as shown
in the protection activities of the ethylene glycol analog and 3-L-2-PC.

IT 19420-57-6P 22248-66-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation of lysophosphatidylcholine analogs from D-mannitol as chiral
template and their protective activity for sepsis)

RN 19420-57-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-
10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 22248-66-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-
10-oxo-, inner salt, 4-oxide, (7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:452371 CAPLUS

DOCUMENT NUMBER: 143:126689

TITLE: Suppression of HMGB1 release by stearyl
lysophosphatidylcholine as an additional mechanism for
its therapeutic effects in experimental sepsis

AUTHOR(S): Chen, Guoqian; Li, Jianhua; Qiang, Xiaoling; Czura,
Christopher J.; Ochani, Mahendar; Ochani, Kanta;
Ulloa, Luis; Yang, Huan; Tracey, Kevin J.; Wang, Ping;
Sama, Andrew E.; Wang, Haichao

CORPORATE SOURCE: Department of Emergency Medicine, New York University
School of Medicine, North Shore University Hospital,

Manhasset, NY, 11030, USA

SOURCE: Journal of Lipid Research (2005), 46(4), 623-627
CODEN: JLPRAW; ISSN: 0022-2275

PUBLISHER: American Society for Biochemistry and Molecular Biology, Inc.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Stearoyl lysophosphatidylcholine (LPC) has recently been proven protective against lethal sepsis by stimulating neutrophils to eliminate invading pathogens through an H2O2-dependent mechanism. Here, we demonstrate that stearoyl LPC, but not caproyl LPC, significantly attenuates circulating high-mobility group box 1 (HMGB1) levels in endotoxemia and sepsis by suppressing endotoxin-induced HMGB1 release from macrophages/monocytes. Neutralizing antibodies against G2A, a potential cell surface receptor for LPC, partially abrogated stearoyl LPC-mediated suppression of HMGB1 release. Thus, stearoyl LPC confers protection against lethal exptl. sepsis partly by facilitating the elimination of the invading pathogens and partly by inhibiting endotoxin-induced release of a late proinflammatory cytokine, HMGB1.

IT 17364-19-1, Stearoyl lysophosphatidylcholine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppression of HMGB1 release by stearoyl lysophosphatidylcholine as an addnl. mechanism for its therapeutic effects in exptl. sepsis)

RN 17364-19-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:87658 CAPLUS

DOCUMENT NUMBER: 140:281017

TITLE: Therapeutic effects of lysophosphatidylcholine in experimental sepsis

AUTHOR(S): Yan, Ji-Jing; Jung, Jun-Sub; Lee, Jung-Eun; Lee, Jongho; Huh, Sung-Oh; Kim, Hee-Sung; Jung, Kyeong Cheon; Cho, Jae-Young; Nam, Ju-Suk; Suh, Hong-Won; Kim, Yung-Hi; Song, Dong-Keun

CORPORATE SOURCE: Institute of Natural Medicine, College of Medicine, Department of Pharmacology, Hallym University, 1 Okchon-dong, Chunchon, Gangwon-do, 200-702, S. Korea

SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(2), 161-167
CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sepsis represents a major cause of death in intensive care units. Here we show that administration of lysophosphatidylcholine (LPC), an endogenous lysophospholipid, protected mice against lethality after cecal ligation and puncture (CLP) or i.p. injection of Escherichia coli. In vivo treatment with LPC markedly enhanced clearance of i.p. bacteria and blocked CLP-induced deactivation of neutrophils. In vitro, LPC increased bactericidal activity of neutrophils, but not macrophages, by

enhancing H2O2 production in neutrophils that ingested E. coli. Incubation with an antibody to the LPC receptor, G2A, inhibited LPC-induced protection from CLP lethality and inhibited the effects of LPC in neutrophils. G2A-specific antibody also blocked the inhibitory effects of LPC on certain actions of lipopolysaccharides (LPS), including lethality and the release of tumor necrosis factor- α (TNF- α) from neutrophils. These results suggest that LPC can effectively prevent and treat sepsis and microbial infections.


IT 17364-19-1, Stearoyl lysophosphatidylcholine

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mechanisms of protection effects of lysophosphatidylcholine in prognosis of exptl. sepsis)

RN 17364-19-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:777603 CAPLUS

DOCUMENT NUMBER: 139:286337

TITLE: Novel therapeutical use of agonist ligands specific to G2A receptor

INVENTOR(S): Kim, Yung-Hi; Song, Dong-Keun; Suh, Hong-Won; Huh, Sung-Oh

PATENT ASSIGNEE(S): Biosynergen, Inc., S. Korea

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080071	A1	20031002	WO 2003-KR593	20030325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2003094515	A	20031218	KR 2002-16029	20020325
KR 2004017613	A	20040227	KR 2002-49766	20020822
KR 2004034220	A	20040428	KR 2002-64308	20021021
CA 2480429	A1	20031002	CA 2003-2480429	20030325
AU 2003215954	A1	20031008	AU 2003-215954	20030325
EP 1490072	A1	20041229	EP 2003-745031	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1646138	A	20050727	CN 2003-808899	20030325

JP 2005526789	T	20050908	JP 2003-577897	20030325
US 2005288254	A1	20051229	US 2004-509300	20040924
IN 2006DN06907	A	20070831	IN 2006-DN6907	20061120
PRIORITY APPLN. INFO.:			KR 2002-16029	A 20020325
			KR 2002-49766	A 20020822
			KR 2002-64308	A 20021021
			WO 2003-KR593	W 20030325
			IN 2004-DN3071	A3 20041007

OTHER SOURCE(S): MARPAT 139:286337

AB The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingosylphosphorylcholine) or derivs. thereof to the subject. The agonist ligands for G2A receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.

IT 17364-16-8, 1-Palmitoyllysophosphatidylcholine 19420-56-5
19420-57-6 20559-16-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(agonist ligands specific to G2A receptors such as lysophosphatidylcholines and their derivs. for treatment of diseases associated with neutrophil accumulation or excessive release of IL-8)

RN 17364-16-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 19420-56-5 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R,18Z)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 19420-57-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 20559-16-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2007:127967 USPATFULL

TITLE: Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition

INVENTOR(S): Shi, Song, Reisterstown, MD, UNITED STATES
Moore, Richard, Glenville, PA, UNITED STATES
Gentle, Thomas, Saint Michael, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007111316	A1	20070517
APPLICATION INFO.:	US 2006-541412	A1	20060928 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-721833P	20050928 (60)
	US 2006-762911P	20060127 (60)
	US 2006-841407P	20060830 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BECTON, DICKINSON AND COMPANY, ATTN: DAVID W. HIGHET, 1 BECTON DRIVE, FRANKLIN LAKES, NJ, 07417-1880, US

NUMBER OF CLAIMS: 71

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Page(s)

LINE COUNT: 4431

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods and compositions useful for the diagnosis or prognosis of a systemic inflammatory condition such as sepsis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17364-16-8, 1-O-Palmitoyl-2-lyso-sn-glyero-3-phosphocholine
19420-57-6, 1-O-Stearoyl-2-lyso-sn-glyero-3-phosphocholine
932699-37-1


(detection of lysophosphatidylcholine for prognosis or diagnosis of systemic inflammatory conditions)

RN 17364-16-8 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-

10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 19420-57-6 USPATFULL

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 932699-37-1 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosane-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, sodium salt (1:1), (7R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

L6 ANSWER 10 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2007:114794 USPATFULL

TITLE: Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

INVENTOR(S): Harats, Dror, Ramat-Gan, ISRAEL
George, Jacob, Tel Aviv, ISRAEL
Halperin, Gideon, Har-Adar, ISRAEL
Mendel, Itzhak, Rechovot, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007099868	A1	20070503
APPLICATION INFO.:	US 2006-528657	A1	20060928 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2006-567543, PENDING A 371 of International Ser. No. WO 2004-IL453, filed on 27 May 2004 Continuation of Ser. No. US 2003-445347, filed on 27 May 2003, GRANTED, Pat. No. US 6838452		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: Martin D. MOYNIHAN, PRTSI, Inc., P.O. Box 16446,
Arlington, VA, 22215, US
NUMBER OF CLAIMS: 90
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Page(s)
LINE COUNT: 4699
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel synthetic oxidized lipids and methods utilizing oxidized lipids
for treating and preventing an inflammation associated with an
endogenous oxidized lipid are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17364-16-8

(oxidized lipids for treatment of inflammatory diseases and disorders)

RN 17364-16-8 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-
10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L6 ANSWER 11 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2007:36890 USPATFULL

TITLE: Peptides and peptide mimetics to treat pathologies
characterized by an inflammatory response

INVENTOR(S): Fogelman, Alan M., Beverly Hills, CA, UNITED STATES
Navab, Mohamad, Los Angeles, CA, UNITED STATES

PATENT ASSIGNEE(S): The Regents of the University of California (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007032430	A1	20070208
APPLICATION INFO.:	US 2006-407390	A1	20060418 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-423830, filed on 25 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2002-273386, filed on 16 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-187215, filed on 28 Jun 2002, GRANTED, Pat. No. US 7144862 Continuation-in-part of Ser. No. US 2001-896841, filed on 29 Jun 2001, GRANTED, Pat. No. US 6933279 Continuation-in-part of Ser. No. US 2000-645454, filed on 24 Aug 2000, GRANTED, Pat. No. US 6664230		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-697495P	20050707 (60)
	US 2005-676431P	20050429 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US	
NUMBER OF CLAIMS:	76	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	10947	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17364-16-8D, 1-Palmitoyl-sn-glycero-3-phosphorylcholine, epoxyisoprostane derivs. 19420-57-6D, 1-Stearoyl-sn-glycero-3-phosphorylcholine, epoxyisoprostane derivs.

(peptidic compds. to treat diseases characterized by inflammatory response)

RN 17364-16-8 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 19420-57-6 USPATFULL

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 12 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2007:24315 USPATFULL

TITLE: Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung diseases

INVENTOR(S): Nyce, Jonathan W., Titusville, NJ, UNITED STATES
Pabalan, Jonathan, Burlington, NJ, UNITED STATES
Aguilar, Douglas, Hackensack, NJ, UNITED STATES
Miller, Shoreh, Plainsboro, NJ, UNITED STATES
Li, Yukui, Cambridge, MA, UNITED STATES
Sandrasagra, Anthony, Princeton, NJ, UNITED STATES
Katz, Evan, North Brunswick, NJ, UNITED STATES
Tang, Lei, Princeton, NJ, UNITED STATES
Shahabuddin, Syed, Newton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007021360	A1	20070125
APPLICATION INFO.:	US 2002-475684	A1	20020423 (10)
	WO 2002-US13135		20020423
			20040831 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-286137P	20010424 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050, US	
NUMBER OF CLAIMS:	115	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	6500	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		


AB A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, bronchoconstriction, lung allergy(ies) or inflammation, and abnormal levels of adenosine, adenosine receptors, sensitivity to adenosine, lung surfactant and ubiquinone, such as pulmonary fibrosis, vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, COPD, RDS, ARDS, cancer, and others. The present treatment is effectively administered by itself for conditions without known therapies, as a substitute for therapies exhibiting undesirable side effects, or in combination with other treatments, e.g. before, during and after other respiratory system therapies, radiation, chemotherapy, antibody therapy and surgery, among others. Each of the agents of this invention may be administered directly into the respiratory system so that they gain direct access to the lungs, or by other effective routes of administration. A kit comprises a delivery device, the agents and instructions for its use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17364-18-0, Palmitoyllysophosphatidylcholine
(surfactant formulation containing; treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent)

RN 17364-18-0 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



L6 ANSWER 13 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2005:331269 USPATFULL

TITLE: Novel therapeutical use of agonist ligands specific to g2a receptor

INVENTOR(S): Kim, Yung-Hi, 201-607 Hyundai Apt. 427 Hupyung-dong,,
Chunchon, Kangwon-do, KOREA, REPUBLIC OF 200-959
Song, Dong-Keun, Kangwon-do, KOREA, REPUBLIC OF
Suh, Hong-Won, Kangwon-do, KOREA, REPUBLIC OF
Huh, Sung-Oh, Kangwon-do, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005288254	A1	20051229
APPLICATION INFO.:	US 2003-509300	A1	20030325 (10)
	WO 2003-KR593		20030325

	NUMBER	DATE
PRIORITY INFORMATION:	KR 2002-16029	20020325
	KR	20020822
	KR	20021021
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL BEST & FRIEDRICH, LLP, ONE SOUTH PINCKNEY STREET, P O BOX 1806, MADISON, WI, 53701, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1136	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according hours after CLP according to the present invention and pharmaceutical or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17364-16-8, 1-Palmitoyllysophosphatidylcholine 19420-56-5
19420-57-6 20559-16-4

(agonist ligands specific to G2A receptors such as lysophosphatidylcholines and their derivs. for treatment of diseases associated with neutrophil accumulation or excessive release of IL-8)

RN 17364-16-8 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 19420-56-5 USPATFULL


CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R,18Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 19420-57-6 USPATFULL
 CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 20559-16-4 USPATFULL
 CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 14 OF 14 USPATFULL on STN
 ACCESSION NUMBER: 1998:104830 USPATFULL
 TITLE: Carbonothioate phospholipid analogs as substrate of phospholipases and lipases
 INVENTOR(S): Yu, Lin, San Diego, CA, United States
 Termansky, Robert John, Carlsbad, CA, United States
 PATENT ASSIGNEE(S): LaJolla Pharmaceuticals Co., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5801260		19980901
APPLICATION INFO.:	US 1995-476258		19950607 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Geist, Gary		
ASSISTANT EXAMINER:	Carr, Deborah D.		
LEGAL REPRESENTATIVE:	Morrison & Foerster, LLP		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	413		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel substrates of phospholipases, lysophospholipases and lipases are disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 160118-49-0P

(preparation of carbonothioate glycerophospholipids as substrate of phospholipases and lipases)

RN 160118-49-0 USPATFULL
 CN 3,5,9-Trioxa-4-phosphahexadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 17364-16-8 22248-63-1

(preparation of carbonothioate glycerophospholipids as substrate of phospholipases and lipases)

RN 17364-16-8 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 22248-63-1 USPATFULL

CN 3,5,9-Trioxa-4-phosphanadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (7R)- (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 15:12:17 ON 11 OCT 2007)

FILE 'REGISTRY' ENTERED AT 15:12:35 ON 11 OCT 2007

E "LYSOPHOSPHATIDYLCHOLINE"/CN 25

L1 1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:13:58 ON 11 OCT 2007

L2 5 S L1

FILE 'REGISTRY' ENTERED AT 15:22:34 ON 11 OCT 2007

L3 STRUCTURE UPLOADED

L4 175 S L3 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:23:14 ON 11 OCT 2007

L5 1595 S L4

L6 14 S L5 AND (SEPSIS OR SEPTIC SHOCK)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

97.19

317.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.46

-8.58

STN INTERNATIONAL LOGOFF AT 15:27:57 ON 11 OCT 2007

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3	"5801260"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/10/11 15:27
L2	1678	lysophosphatidylcholine	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/10/11 15:28
L3	128	lysophosphatidylcholine and sepsis	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/10/11 15:30
L4	0	lysophosphatidylcholine near4 sepsis	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/10/11 15:30
L5	33	lysophosphatidylcholine same sepsis	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/10/11 15:31
L6	167	lysophosphatidylcholine.clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/10/11 15:32
L7	3	lysophosphatidylcholine.clm. and sepsis	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/10/11 15:31